AMP-activated protein kinase:a cellular energy sensor that comes in twelve flavours by Ross, Fiona A. et al.
                                                              
University of Dundee
AMP-activated protein kinase
Ross, Fiona A.; MacKintosh, Carol; Hardie, D Grahame
Published in:
FEBS Journal
DOI:
10.1111/febs.13698
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Ross, F. A., MacKintosh, C., & Hardie, D. G. (2016). AMP-activated protein kinase: a cellular energy sensor that
comes in twelve flavours. FEBS Journal, 283(16), 2987-3001. DOI: 10.1111/febs.13698
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Feb. 2017
STATE-OF-THE-ART REVIEW
AMP-activated protein kinase: a cellular energy sensor
that comes in 12 flavours
Fiona A. Ross1, Carol MacKintosh2 and D. Grahame Hardie1
1 Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Scotland, UK
2 Division of Cell and Developmental Biology, School of Life Sciences, University of Dundee, Scotland, UK
Keywords
2R-ohnologue; adenine nucleotides
AMP-activated protein kinase; cancer;
energy homeostasis; LKB1; oncogene;
tumour suppressor
Correspondence
D. G. Hardie, Division of Cell Signalling &
Immunology, School of Life Sciences,
University of Dundee, Dundee DD1 5EH,
Scotland, UK
Fax: +44 (0) 1382 385507
E-mail: d.g.hardie@dundee.ac.uk
(Received 7 January 2016, revised 10
February 2016, accepted 29 February 2016)
doi:10.1111/febs.13698
The AMP-activated protein kinase (AMPK) is a sensor of cellular energy
status that is expressed in essentially all eukaryotic cells, suggesting that it
arose during early eukaryotic evolution. It occurs universally as heterotri-
meric complexes containing catalytic a subunits and regulatory b and c sub-
units. Although Drosophila melanogaster contains single genes encoding
each subunit, in mammals, each subunit exists as multiple isoforms encoded
by distinct genes, giving rise to up to 12 heterotrimeric combinations. The
multiple isoforms of each subunit are 2R-ohnologues generated by the two
rounds of whole genome duplication that occurred at the evolutionary origin
of the vertebrates. Although the differential roles of these isoform combina-
tions remain only partly understood, there are indications that they may
have different subcellular locations, different inputs and outputs, and differ-
ent functions. The multiple isoforms are of particular interest with respect to
the roles of AMPK in cancer because the genes encoding some isoforms,
such as PRKAA1 and PRKAB2 (encoding a1 and b2), are quite frequently
amplified in tumour cells, whereas the genes encoding others, such as
PRKAA2 (encoding a2), tend to be mutated, which, in some but not all
cases, may result in a loss of function. Thus, although AMPK acts down-
stream of the tumour suppressor liver kinase B1, and some of its isoform
combinations may act as tumour suppressors that restrain the growth and
proliferation of tumour cells, other isoform combinations may paradoxically
act as oncogenes, perhaps by aiding the survival of tumour cells undergoing
environmental stresses such as hypoxia or nutrient deprivation.
Introduction
The AMP-activated protein kinase (AMPK) is a sen-
sor of cellular energy status expressed in essentially all
eukaryotic cells, including protists, fungi, plants and
animals [1–3]. AMPK orthologues appear to exist uni-
versally as heterotrimeric complexes comprised of cat-
alytic a subunits and regulatory b and c subunits. In
invertebrate species such as Drosophila melanogaster
the a, b and c subunits of the AMPK orthologue are
encoded by single genes [4]. However, in vertebrates,
all three subunits exist as multiple isoforms encoded
by distinct genes [5–7]. In humans, the a1 and a2 iso-
forms are encoded by PRKAA1 and PRKAA2, the b1
Abbreviations
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and b2 isoforms by PRKAB1 and PRKAB2, and the
c1, c2 and c3 isoforms by PRKAG1, PRKAG2 and
PRKAG3. These seven subunit isoforms could poten-
tially give rise to as many as 12 heterotrimeric combi-
nations. Co-expression of different combinations in
mammalian cells suggests that all 12 heterotrimers can
be generated (D. G. Hardie, unpublished data),
whereas at least six different combinations have been
generated by expression in bacteria [8]. However, there
are indications that specific combinations are favoured
in specific cell types: for example, although skeletal
muscle appears to express all seven subunit isoforms at
the mRNA level [5–7], studies using isoform-specific
immunoprecipitation suggest that AMPK activity in
that tissue can be accounted for by just three combina-
tions: a1b2c1, a2b2c1 and a2b2c3 [9].
As yet, the question of whether these distinct hetero-
trimeric combinations have different functions has not
received much attention, although interesting new evi-
dence is beginning to emerge. Here, we review these
findings, which suggest that the different combinations
may be present at different subcellular locations, have
different regulatory properties, and have different
inputs and outputs. As will be discussed, this issue
may be particularly important when considering the
roles of AMPK in cancer.
Origin of multiple isoforms of AMPK:
evolution of 2R-ohnologues
It is now believed that two rounds of whole genome
duplication (1R and 2R) occurred early in the evolu-
tion of the vertebrates, although, in most cases, from
one to three of the four gene copies produced by this
process were subsequently lost [10]. Approximately 20–
30% of human genes occur as paralogues produced by
these events, and these are known as 2R-ohnologues
in honour of Susumu Ohno who proposed the 2R
hypothesis [11]. The marine chordate amphioxus
(Branchiostoma floridae) diverged from the vertebrate
lineage before these gene duplication events, and is
perhaps the best living proxy for the ancestral inverte-
brate because its genome generally contains a single
pro-orthologue for each family of vertebrate 2R-ohno-
logues [12].
The criteria to assign paralogous vertebrate genes as
2R-ohnologues are: (a) they are typically on different
chromosomes, in blocks called paralogons that retain
the gene content and order of the ancestral region
from which they derive; (b) there should be a single
pro-orthologue in amphioxus in a chromosomal region
showing evidence of synteny with up to four corre-
sponding vertebrate paralogons; (c) the phylogenetic
tree should have a symmetrical topology arising
because the 1R generated two precursor genes, which in
turn were both duplicated simultaneously in the 2R to
generate four vertebrate genes relative to a single inver-
tebrate gene (Fig. 1A); and (d) the paralogues should
share similar domain architectures. Because of the 500
million years of genome rearrangements, mutations
and losses since the 2R occurred, few 2R-ohnologue
families fit these criteria perfectly, although there are
sufficient collective data to confidently designate the
a, b and c subunits of AMPK as three families of
2R-ohnologues. As an example, Figs 1B, 1C and 2B
illustrate criterion (c) for the c subunits, criterion (a)
for the a subunits, and criterion (d) for all three sub-
units, respectively. This is in keeping with the observa-
tion that the few thousand families of 2R-ohnologues
retained in modern-day vertebrates are highly enriched
in genes encoding regulatory proteins, including
cytokines, growth factors, ion channels, receptors, G
proteins, regulated metabolic enzymes, transcription
factors and protein kinases [13–16]. One implication of
this is that the 2R-WGD provided an evolutionary
leap in cellular communication; a quadrupling of the
signalling pathways available to our last common
invertebrate ancestor may have enabled the great
increase in complexity and variety of the vertebrates
that followed.
Canonical regulation of AMPK and
structure of heterotrimeric complexes
Mammalian AMPK complexes sense cellular energy
status by monitoring the levels of AMP, ADP and
ATP. Any rise in the ADP : ATP ratio, indicating a
falling cellular energy (analogous to a flat battery), is
converted by the adenylate kinase reaction into a
much larger rise in AMP : ATP [17]. The latter
appears to be the primary signal that switches on
AMPK, although increases in ADP may have a sec-
ondary effect [17–20]. Once activated, AMPK attempts
to restore energy homeostasis by switching on alter-
nate catabolic pathways that generate ATP, at the
same time as switching off energy-consuming pro-
cesses, including cell growth and proliferation. A
recent review [3] listed over 60 well-validated direct
targets for AMPK phosphorylation, and it is likely
that the list will eventually extend into the hundreds.
Before considering the differential roles of specific
isoforms, we review the features common to all hetero-
trimeric AMPK complexes in mammals. Figure 2A
shows the structure of the human a1b2c1 heterotrimer
[21], which is similar to earlier structures for the
a2b1c1 [22] and a1b1c1 [23] complexes, while Fig. 2B
2988 The FEBS Journal 283 (2016) 2987–3001 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
AMPK: a cellular energy sensor in 12 flavours F. A. Ross et al.
shows the layout of domains and other points of inter-
est on the seven human subunit isoforms.
Domain layout of the a subunits
The a1 and a2 subunits contain N-terminal kinase
domains (a-KD) typical of the eukaryotic protein
kinase family, with the active site (occupied in Fig. 2A
by the kinase inhibitor staurosporine) in the cleft
between the small N-lobe and larger C-lobe. Phospho-
rylation by upstream kinases of a conserved threonine
within the activation loop (usually referred to as
Thr172, although the numbering varies in different
species and isoforms) can increase the kinase activity
by > 100-fold. The major upstream kinases phosphory-
lating Thr172 are the tumour suppressor kinase liver
kinase B1 (LKB1) in complex with the accessory sub-
units STRAD and MO25, and the Ca2+/calmodulin-
dependent protein kinase CaMKK2 (CaMKKb) [1–3].
The a-KD is followed by the auto-inhibitory domain
(a-AID), a compact bundle of three a-helices. In struc-
tures of a-KD:a-AID constructs, which invariably
have a low activity [8,21,24], the a-AID appears to
inhibit the a-KD by binding to its N- and C-lobes on
the ‘back’ side (i.e. opposite to the active site), holding
it in a less active conformation. By contrast, in active
conformations such as that shown in Fig. 2A, the
a-AID has rotated away from the N-lobe and binds to
the c subunit instead. The a-AID is followed by a flex-
ible a-linker that connects it to the globular C-terminal
domain (a-CTD); this linker is crucial in regulation by
adenine nucleotides, as is discussed further in the sec-
tion on c subunits below.
Domain layout of the b subunits
A conserved MGNXXS sequence at the N-terminus
of b subunits from the animal kingdom fits the con-
sensus for N-myristoylation, and the human b1 and
b2 subunits are indeed myristoylated on Gly2 after
removal of the initiating methionine [25]. When wild-
type b1, or a non-myristoylated (G2A) mutant, was
co-expressed with GFP-tagged a1 and c1 in COS7
cells, glucose starvation caused the fluorescence asso-
ciated with the wild-type, but not the mutant, to shift
from a diffuse cytoplasmic distribution to perinuclear
speckles [25]. Although these speckles were not identi-
fied, it is tempting to speculate that they represent
Fig. 1. Results supporting the assignments of human AMPK subunits as members of 2R-ohnologue families. (A) An idealized phylogenetic
tree for a family of four human 2R-ohnologues. (B) A phylogenetic cladogram derived from TreeFam (family TF313247) (http://
www.treefam.org) [81] shows that the human PRKAG1, PRKAG2 and PRKAG3 proteins cluster into three paralogy groups. Although some
nodes have low bootstrap values, the tree topology is consistent with a single invertebrate pro-orthologue giving rise to two genes in the
1R during early vertebrate evolution: one of these genes then generated PRKAG1 and PRKAG3 in the 2R, whereas duplication of the other
generated PRKAG2 and a fourth gene that has been lost (no PRKAG1 gene could be identified in chickens). A third genomic duplication (3R)
that occurred in the last common ancestor of the teleost fish may explain the additional PRKAG2 and PRKAG3 genes in zebrafish. Draft
sequences of pro-orthologues of AMPK subunits in B. floridae (an amphioxus species) have the UniProt identifiers: alpha (C3YCL4), beta
(C3Y0T7) and gamma (C3YBW1). (C) Simplified map of the regions of chromosomes 5 and 1 that share synteny and contain the PRKAA1
and PRKAA2 genes, respectively; DAB2 and DAB1 and C6 and C8A are also pairs of 2R-ohnologues.
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lysosomes because glucose starvation has been
reported to cause relocalization of AMPK to lyso-
somes as a result of its association with a complex
containing AXIN and the resident lysosomal protein
LAMTOR1. Because AXIN also binds LKB1, this
relocalization to the lysosome is proposed to increase
Thr172 phosphorylation and activation of AMPK in
response to glucose starvation [26]. An alternative
role of N-myristoylation of the b subunits, not neces-
sarily mutually exclusive, was reported by Liang et al.
[27], who proposed a role for AMPK in the selective
removal of damaged mitochondria by autophagy, and
suggested that this requires myristoylation of the b1
subunit to assist in binding of AMPK to mitochon-
drial membranes.
The myristoylated N-termini are followed by vari-
able sequences of approximately 100 amino acids; the
structures of these regions are not known because all
heterotrimer structures were determined with truncated
b subunits lacking them. They are followed by the car-
bohydrate-binding module (b-CBM), which is con-
nected by a linker that is poorly resolved in crystal
structures to the C-terminal domain (b-CTD). The lat-
ter forms the core of the heterotrimeric complex,
bridging the a and c subunits, whereas, in all struc-
tures of active heterotrimers, the b-CBM perches on
top of the N-lobe of the a-KD (Fig. 2A). The b-CBM
is a member of the CBM48 family [28], whose mem-
bers comprise noncatalytic domains that bind polyglu-
cans such as starch or glycogen, usually found as
components of enzymes that metabolize such polysac-
charides. In mammals, the b-CBM causes a proportion
of cellular AMPK to bind to glycogen [29,30]; the
function of this is not well understood, although it
would co-localize AMPK with glycogen synthase, both
isoforms of which (GYS1/GYS2) are bound to glyco-
Fig. 2. (A) Structure of the human a1b2c1 complex and (B) domain diagrams for the human subunit isoforms. Atomic coordinates in (A) are
from Protein Data Bank entry: 4RER [21] and the model was rendered in space-filling mode in PYMOL, version 1.7.4.2 (Schr€odinger, LLC,
New York, NY, USA). The glycogen-binding and catalytic sites in this structure are occupied by b-cyclodextrin (C atoms, green; O, red) and
staurosporine (blue); the ADaM site was empty but the position of phospho-Ser108 (C, green; O, red) indicates its location. AMP was
bound in sites 1, 3 and 4, although only that in site 3 is visible (red); the other two are around the back of the c subunit in this view.
Phospho-Thr172 is also round the back in this view. The domain diagrams in (B) are drawn approximately to scale; domains referred to in
the text are given similar colour coding in (A) and (B).
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gen particles and are inactivated by AMPK phospho-
rylation [31,32].
The b-CBM in mammalian AMPK has a second
function, in that the cleft between it and the N-lobe of
the a-KD forms the binding site for ligands such as
A769662 and 991, which are synthetic compounds
derived from high-throughput screens that searched
for allosteric AMPK activators [22,23,33]. This binding
cleft is stabilized by autophosphorylation of Ser108 on
the b-CBM (Fig. 2A), whose phosphorylated side
chain interacts with two conserved lysines on the
a-KD N-lobe [22]. It has been termed the allosteric
drug and metabolite (ADaM) binding site, although
no natural metabolite derived from mammals has yet
been shown to bind there. However, salicylate, the
natural plant product used as a medicine ever since
ancient times, and from which acetyl salicylic acid
(aspirin) was derived, activates AMPK by binding to
the ADaM site [23,34].
Domain layout of the c subunits
The c subunits contain variable N-terminal domains
that will be discussed further below, followed by four
tandem repeats [cystathionine b-synthase repeats 1–4
(CBS1–CBS4)] of a sequence motif known as a CBS
repeat. These also occur (although usually as just two
repeats) in a small number of other proteins in the
human genome where they have been shown to bind
regulatory ligands containing adenosine, such as ATP
or S-adenosyl methionine, in the cleft between each
pair of repeats [35]. In the AMPK-c subunits, the four
repeats fold into a disk-like shape with one repeat in
each quadrant, generating four pseudosymmetrical
clefts in the centre that comprise the binding sites for
the regulatory nucleotides AMP, ADP and ATP [35].
However, crystal structures suggest that only three of
these, designated site 1 (between CBS1 and CBS2) and
sites 3 and 4 (between CBS3 and CBS4) are ever occu-
pied [19,22,36].
Binding of AMP to the c subunit activates AMPK
by three mechanisms [17]: (a) allosteric activation; (b)
promotion of Thr172 phosphorylation by LKB1; and
(c) inhibition of Thr172 dephosphorylation by protein
phosphatases. Although the roles of the three AMP-
binding sites are not completely understood, the criti-
cal site for mechanisms (a) and (c) appears to be site
3. The a-linker mentioned earlier contains two con-
served sequence motifs termed a-RIM1 and a-RIM2
(where RIM is the regulatory subunit interaction
motif). In all three structures of active human hetero-
trimers [21–23], which have AMP bound at sites 1, 3
and 4, a-RIM1 interacts with the surface of CBS2
close to the unoccupied site 2, whereas a-RIM2 inter-
acts with the surface of CBS3 via residues that also
interact with the AMP bound in site 3 (Fig. 2A). The
a-AID and a-linker appear to form a flexible hinge
between two regions of the heterotrimer termed the
catalytic module (containing the a-KD and b-CBM;
Fig. 2A, top left) and the nucleotide-binding module
(containing the a-CTD, b-CTD and c subunit;
Fig. 2A, bottom right). A current model based on var-
ious structural, biophysical and mutational analyses
[21–24,37–40] suggests that AMP binding at site 3 pro-
motes the interaction between the a-RIM2 sequence
and CBS3, causing the a-linker to ‘pull’ the a-AID
away from its inhibitory interaction behind the a-KD
and thus explaining allosteric activation by AMP.
Conversely, when ATP is bound at site 3, the a-linker
dissociates from the c subunit, allowing the a-AID to
rotate back into its inhibitory position behind the
a-KD. The partial separation of the catalytic and
nucleotide-binding modules allowed by this release of
the a-linker may also make Thr172 more accessible to
protein phosphatases, explaining how ATP binding
relieves the protective effect of AMP on Thr172
dephosphorylation [mechanism (c)]. This model leaves
open the functions of nucleotide binding at sites 1 and
4, although, as a result of the three binding sites lying
very close together at the centre of the c subunit, it is
inevitable that there will be interactions between them.
AMPK: tumour suppressor or
oncogene?
We now briefly consider the role of AMPK in cancer,
which will become relevant to our subsequent discus-
sion of the functions of the different subunit isoforms.
AMPK is known to inhibit cell growth, not only
directly by inhibiting biosynthetic pathways such as
lipid, glycogen and rRNA biosynthesis, but also indi-
rectly by inactivating a key signalling node that pro-
motes cell growth, the mechanistic target-of-rapamycin
complex-1 [1–3]. AMPK can also inhibit cell prolifera-
tion by causing a G1 cell cycle arrest [41,42]. Given
these potential cytostatic effects, it had been widely
assumed that AMPK exerts many, if not all, of the
tumour suppressor functions of its upstream kinase,
LKB1. Supporting this are findings showing that
whole-body knockout of AMPK-a1 in mice acceler-
ated the development of lymphomas driven by over-
expression of the oncogene Myc in B cells [43]. If
AMPK is a tumour suppressor, there would also be
selection pressure for it to be down-regulated in can-
cers. This does indeed occur by various mechanisms
in different cancers, including phosphorylation of
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AMPK-a1 at Ser487 by Akt, which inhibits its subse-
quent phosphorylation at Thr172 and activation by
LKB1 [44], and degradation of AMPK-a1 following
polyubiquitylation by the E3 ligase TRIM28, which is
targeted to AMPK by MAGE-A3/-A6; the latter were
originally defined as tumour antigens normally only
expressed in testis, but also aberrantly re-expressed in
many cancers [45].
Despite this, it now appears that a complete loss of
AMPK function, particularly in solid tumours, may
limit their viability by reducing their tolerance to stres-
ses such as hypoxia, glucose deprivation or oxidative
stress. The first evidence for this view came from stud-
ies of H-Ras-transformed mouse embryo fibroblasts
(MEFs) with/without a double AMPK-a1/a2 knock-
out, where it was found that the knockout cells grew
normally in vitro but failed to grow in vivo in immun-
odeficient mice [46]. The inference was that the cells
were viable in the rich medium of a culture dish but
not in the tougher environment in vivo, where the sup-
ply of oxygen and nutrients may often be limiting.
More recently, knocking down or knocking out
AMPK has been shown to reduce the growth or via-
bility of tumour cells in several different in vitro and
in vivo models; a more comprehensive coverage is pro-
vided elsewhere [47–50]. These findings have resulted
in a modified view of the role of AMPK in cancer.
Thus, AMPK may initially limit the rapid growth and
proliferation of incipient tumour cells, such that they
would be under selection pressure to down-regulate
the pathway and reduce its restraining influence. How-
ever, a complete loss of AMPK might paradoxically
create a severe disadvantage to the tumour cells, ren-
dering them more vulnerable to the stresses that occur
as they outgrow the capacity of their blood supply to
deliver oxygen and nutrients. This new synthesis of the
roles of AMPK in cancer is considered further below.
Differential functions of complexes
containing different subunit isoforms
Differences between a1 and a2 (PRKAA1 and
PRKAA2)
The sequences of the human a1 and a2 isoforms are
90% identical within the kinase domains, and early
work using peptide substrates suggested that their sub-
strate specificities were similar, if not identical [51].
Most cell types express both isoforms, although cells
in the haemopoietic lineage only express a1. This helps
to explain the most obvious phenotype of a1 knockout
mice, which concerns erythrocytes. Erythrocytes lack-
ing a1 have rigid and nondeformable plasma
membranes, and are therefore more susceptible to
damage by shear stress during passage through capil-
laries, triggering severe anaemia [52]. By contrast, a2
knockout mice have a quite different phenotype: they
are insulin-resistant and glucose-intolerant, apparently
as a result of an overactive sympathetic nervous sys-
tem and consequent hyper-secretion of adrenaline (epi-
nephrine), which inhibits insulin secretion and action
[53]. Because several different hormones inhibit
AMPK in the ventromedial hypothalamus and simul-
taneously activate the sympathetic nervous system [54–
56], the phenotype of global a2 knockout might be
caused by its loss in hypothalamic neurones. Although
whole body a1 or a2 knockouts are therefore viable
albeit with distinct phenotypes, simultaneous knockout
of both a subunits causes embryonic lethality [57].
Thus, although the functions of a1 and a2 are distinct,
each can compensate for loss of the other, except per-
haps in those few cell types where only one is
expressed.
There is some limited evidence showing that the two
catalytic subunit isoforms have different subcellular
locations. This is a neglected topic but is important
because it is likely that much of the substrate selectiv-
ity of the isoforms derives from their distinct subcellu-
lar locations, rather than their intrinsic specificity.
Although neither isoform is exclusively localized to the
nucleus, a2 appears to be more enriched in the nucleus
than a1 in several cell types, including skeletal muscle
[58–60]. In the mouse C2C12 muscle cell line, the
adipokines leptin and adiponectin caused activation
and nuclear translocation of a2 but not a1 [61]. Con-
trasting results were obtained in mouse liver, where a1
expression within the nucleus was found to vary in a
circadian manner, correlating with expression at the
mRNA level of b2 but not b1, whereas the expression
of a2 in the nucleus was constant [62]. Exactly how
AMPK complexes shuttle between the cytoplasm and
the nucleus remains unclear, although a putative
nuclear localization sequence in a2, which is not fully
conserved in a1, has been identified [61]. The a2 iso-
form also has a well-defined and functional nuclear
export sequence (NES) at its extreme C-terminus [63];
a putative NES is also present at the same position in
a1, although it has not yet been shown to be func-
tional.
AMPK has also been reported to localize in stress
granules, regions of cytoplasm that form in cells expe-
riencing metabolic or oxidative stress, which contain
translationally arrested mRNAs and are nucleated by
the protein G3BP1 (Ras GTPase activating protein-
binding protein-1). Interestingly, a2, but not a1, has
been reported to co-localize with stress granules, and
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this may be the result of a direct interaction with
G3BP1 [64].
The two isoforms also differ in their cross-talk with
other signalling pathways. As mentioned above,
AMPK-a1 is phosphorylated at Ser487 (human num-
bering) by the protein kinase Akt, a key downstream
mediator of the insulin/IGF-1 signalling pathways
[44,65]. Ser487 is located within the ST loop, a serine/
threonine-rich sequence of approximately 50 residues
that lies just before the NES at the C-termini of both
a1 and a2 (Fig. 2B). This loop is not present in
AMPK orthologues from most nonvertebrates and, in
its unphosphorylated form, appears to be largely
unstructured because it is not resolved in any of the
heterotrimer structures. However, phosphorylation of
Ser487 by Akt inhibits subsequent Thr172 phosphory-
lation and consequent activation by LKB1, leading to
reduced AMPK activation in various tumour cell lines
in which Akt has been hyper-activated by loss of the
tumour suppressor PTEN [44,65]. The residue equiva-
lent to Ser487 on human a2 is Ser491, which (unlike
Ser487) is an extremely poor substrate for Akt and is
rapidly auto-phosphorylated instead [44]. Thus,
although the ST loop may be a key locus for cross-talk
between AMPK and other signalling pathways, this
appears to occur in an isoform-specific manner.
One of the most striking differences between the a1
and a2 isoforms, as recently noted by Monteverde
et al. [48], emerges from analysis of mutations in the
cancer genome databases using cBioPortal [66,67]. As
befitting a tumour suppressor, the STK11 gene encod-
ing LKB1 is often mutated or deleted in cancers
(Fig. 3A; note the preponderance of green and blue
bars), particularly in lung adenocarcinomas where
mutations occur in 15–20% of cases. A majority
(> 60%) of the mutations that occur in STK11 are
nonsense or splicing mutations, or insertions or dele-
tions (Fig. 4A, red symbols), all of which are likely to
produce nonfunctional proteins. If AMPK did exert
the tumour suppressor functions of LKB1, it might
have been expected that the AMPK genes would also
be either mutated or deleted in different cancers.
However, cBioPortal reveals that, in the same cancer
genome studies where STK11 is mutated or deleted,
the PRKAA1 gene encoding a1 is often amplified,
with the highest frequency (10–15%) also occurring in
lung adenocarcinomas (Fig. 3B; note the preponder-
ance of red bars). By contrast with STK11, mutations
in PRKAA1 are infrequent (approximately 0.1% of
all cancer cases) and around 80% of those that do
occur are missense mutations that may not affect
function (Fig. 4B, green symbols). In the current
CCLE database [68], which covers almost 900 individ-
ual cancer cell lines, PRKAA1 exhibits a major ampli-
fication in 8% and a more moderate gain of gene
copy number in 41%, and there is a correlation
between gene copy number and mRNA expression
(Fig. 5B), suggesting that gene amplification does lead
to increased expression. By contrast, the frequency of
alterations in the PRKAA2 gene (encoding a2) in can-
cer is lower overall (Fig. 3C; note the different scales),
and there is no obvious bias towards gene amplifica-
tion or increased mRNA expression (Fig. 5C). The
frequency of mutations is also much higher for
PRKAA2 than PRKAA1, although the proportions of
missense mutations are quite similar (Figs 3C and
4C). Thus, amplification of the PRKAA1 gene
appears to have been selected for in different cancers,
suggesting that it is an oncogene. By contrast,
PRKAA2 is subject to more frequent mutations and,
although many might be passenger mutations caused
by genomic instability of cancer cells, some may cause
a loss of function consistent with the idea that a2 is a
tumour suppressor.
There is some independent evidence supporting these
divergent roles of a1 and a2 in cancer. As discussed
above, a loss of both a1 and a2 in H-Ras-transformed
MEFs caused a complete failure of their growth
in vivo in immunodeficient mice [46]. Intriguingly, how-
ever, although a loss of PRKAA1 caused failure of
MEFs to grow in vivo just like the double knockouts,
a loss of PRKAA2 alone caused the tumours to grow
more rapidly [69]. Taken together with the other find-
ings discussed here, this suggests that, although
AMPK-a2 might indeed represent a tumour suppres-
sor (similar to its upstream kinase, LKB1), AMPK-a1
may represent instead an oncogene that is frequently
amplified in cancers, perhaps because it protects
tumour cells against stresses caused by lack of oxygen
or nutrients. Our rather limited current insight into the
differential roles of the two a isoforms makes it diffi-
cult to explain these divergent roles in cancer, and
enhancing our understanding in this area represents an
important challenge for the future.
Differences between b1 and b2 (PRKAB1 and
PRKAB2)
Although the b1 and b2 subunit isoforms both contain
a central CBM, the CBM in b2 (an isoform highly
expressed in skeletal muscle, a tissue with high glyco-
gen levels) appears to have a higher affinity for glyco-
gen and glucose oligosaccharides [70]. The surfaces of
the b-CBMs opposite to the glycogen-binding site also
contribute to the ADaM site discussed earlier. All of
the known allosteric activators that bind this site have
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a much higher affinity for complexes containing b1
rather than b2 [8,34,71], although the significance
of this difference may remain unclear unless a physio-
logical ligand that binds the ADaM site can be
identified.
Similar to the a isoforms, an intriguing difference
between b1 and b2 concerns the nature of genetic
changes in the respective genes (PRKAB1 and
PRKAB2) in the cancer genome databases. Analysis
using cBioPortal reveals that changes in PRKAB1 are
Fig. 3. Frequency of alterations in (A)
STK11 (encoding LKB1), (B) PRKAA1
(encoding AMPK-a1) and (C) PRKAA2
(encoding AMPK-a2) displayed using
cBioPortal [66,67] . Data are from a
selected group of 43 cancer genome
studies, and only those with alterations
are displayed. Note how the alterations in
STK11 are most frequently mutations
(although deletions are particularly
prevalent in cervical, ovarian and uterine
cancers), whereas PRKAA1 is quite
frequently amplified. With some
exceptions, alterations in PRKAA2 are
mostly mutations, and the frequency is
lower (note different scales on the y-axes).
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relatively infrequent (generally < 4%) and are a mix-
ture of amplifications, deletions, nonsense and mis-
sense mutations. By contrast, changes in the PRKAB2
gene are more frequent (> 10% in many types of can-
cer) and are almost invariably amplifications [48]. Sim-
ilar to the related findings with the a subunits, it is
currently difficult to explain why b2 is selectively
amplified, based on our limited knowledge of the func-
tional differences between b1 and b2. In many cancer
genome studies, including the Cancer Cell Line
Encyclopedia [68], the PRKAA1 and PRKAB2 genes
(encoding a1 and b2) tend to be amplified together
(P < 0.01), suggesting that there has been selection for
amplification of both genes. This may be because the
over-expressed a1 subunit is unstable unless there is an
increased level of a b subunit with which it can
interact.
Differences between c1, c2 and c3 (PRKAG1,
PRKAG2 and PRKAG3)
The regions of the c subunits whose function is most
well understood are the four tandem CBS repeats at
their C-termini, which, as discussed above, form the
binding sites for the regulatory nucleotides AMP, ADP
and ATP. In a recent study [18], complexes containing
c1, c2 and c3 were expressed in mammalian cells and
shown to display potentially important differences in
their regulation by adenine nucleotides. First, although
c1 and c2 complexes were allosterically activated by up
to 10-fold by AMP, c3 complexes were barely activated
at all (< 1.5-fold). Despite this, all three complexes were
activated in intact cells by agents that increased cellular
AMP/ADP as a result of increased Thr172 phosphory-
lation. This suggested that AMP or ADP were either
promoting phosphorylation or inhibiting dephosphory-
lation, and these possibilities were examined in cell-free
assays. AMP caused a four- to five-fold stimulation of
activation and Thr172 phosphorylation of c1 complexes
by LKB1, with much smaller effects on c2 and c3 com-
plexes. The effect on c1 complexes was also mimicked
by ADP, although only at much higher concentrations.
Binding of either AMP or ADP also protected Thr172
against dephosphorylation in cell-free assays; with c1
and c3 complexes, AMP was almost 10-fold more
potent than ADP, whereas, with c2 complexes, the
potencies of AMP and ADP were similar. Thus, the c1,
c2 and c3 complexes display interesting differences in
the three mechanisms by which adenine nucleotides reg-
ulate AMPK [18].
The most striking differences in sequence between
the three isoforms occur in their N-terminal regions.
Both c2 and c3 contain N-terminal extensions of up to
240 and 150 residues, respectively, which are unrelated
to each other and absent in c1 (Fig. 2B). The c2 and
c3 isoforms also occur as various shorter versions: c3
as one short form with an N-terminal extension
of only 130 residues, and c2 as the full-length form
Fig. 4. Summary of nonsynonomous
mutations in (A) STK11, (B) PRKAA1 and
(C) PRKAA2 in the same set of cancer
studies as in Fig. 3. Red dots indicate the
positions of nonsense, frameshift or
splicing mutations that would give rise to
truncated or aberrantly spliced proteins,
whereas green dots are the positions of
missense mutations, which are less likely
to cause a loss of function.
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(c2-a), and three shorter forms that either lack the N-
terminal extension (c2-b) or have shorter extensions of
approximately 115 (c2-c) and 190 (c2-3B) residues
[72,73]. Most of these appear to be generated via the
use of alternate transcriptional start sites, although c2-
3B, the major form expressed in human heart, is a
splice variant containing 32 unique amino acids at the
N-terminus. Although the functions of these variable
N-terminal extensions in c2 and c3 remain unclear, it
is tempting to speculate that they cause localization of
these isoforms at specific subcellular locations. Indeed,
the different c subunit isoforms do appear to localize
differently in cardiac and skeletal muscle cells [74].
Their precise locations and the proteins that target
them to those locations remain largely unknown,
although c1 (despite having only a very short N-term-
inal extension) emerged as an interacting protein in a
two-hybrid screen using the cytoskeletal protein plectin
as bait, and complexes containing a1 and c1 localized
to the Z disk in wild-type but not in plectin-deficient
skeletal muscle [75]. In human endothelial cells grown
in culture, a2, b2 and c2 appeared to co-localize at the
mid-body during cytokinesis and were also present in
the nucleus, whereas a1, b1 and c1 were largely cyto-
plasmic, with little or no nuclear staining [76]. The
validity of these findings is critically dependent on the
specificity of the antibodies used, although they do
suggest that different isoform combinations may be
present at distinct subcellular locations.
There are also indications that AMPK complexes
containing different c subunit isoforms are regulated
differently and have different downstream targets in
skeletal muscle. Thus, the AMPK activator AICAR,
which is converted to an AMP analogue inside cells,
activates glucose uptake in isolated muscles from wild-
type but not AMPK-c3/ knockout mice, suggesting
a special role for c3 complexes in promoting glucose
uptake. Consistent with this, the alternative activator
PT-1, which, in contrast to previous studies [77], acti-
vates AMPK by inhibiting the mitochondrial respira-
tory chain and thus increasing cellular AMP, was
reported to activate c1 complexes but failed to activate
either c3 complexes or glucose uptake in isolated mus-
cle, despite the fact that it did activate c3 complexes
expressed in HEK293 cells [78]. These results suggest
that c3 complexes are present at a unique location in
muscle that is not reproduced in HEK293 cells, where
their activity (unlike that of c1 complexes) is unaf-
fected by increases in AMP resulting from inhibition
of mitochondrial respiration. Intriguingly, a2b2c3
appears to be the only AMPK complex activated by
contraction in human skeletal muscle [9]. Taking these
findings together, the a2b2c3 complex in muscle
Fig. 5. Correlation between deletion or amplification of the (A)
STK11, (B) PRKAA1 and (C) PRKAA2 genes and mRNA expression
by micro-array (Z-scores). ‘Deep’ and ‘shallow’ deletions most likely
indicate homozygous and heterozygous gene loss, whereas ‘gain’
and ‘amplification’ indicate moderate and substantial gene
amplification, assigned using analysis of single nucleotide
polymorphism arrays. Data were from the Cancer Cell Line
Encyclopedia [68] and were visualized using box and whisper plots;
the boxes show the median and the 25th and 75th percentiles,
whereas the whispers show the top and bottom values. Note that,
with STK11, there is a high proportion of ‘shallow’ and a significant
proportion of ‘deep’ deletions, which shows some correlation with
mRNA expression. By contrast, with PRKAA1, there is a high
proportion of ‘gains’ and a significant proportion of ‘amplifications’,
which also show a clear correlation with mRNA expression. With
PRKAA2, there is no significant bias towards amplification or
deletion or to a change in expression at the mRNA level.
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appears to be able to sense changes in the AMP : ATP
ratio caused by increased ATP turnover by the myosin
ATPase but not those resulting from inhibition of
mitochondrial ATP synthesis. In muscle, PT-1 also
caused increased phosphorylation of ULK1, an
AMPK target involved in regulation of autophagy and
mitophagy, but not targets involved in the regulation
of glucose uptake (TBC1D1) or fatty acid oxidation
(acetyl-CoA carboxylase, ACACB), both of which
were phosphorylated in response to AICAR [78].
These results imply that ULK1 is primarily phospho-
rylated by a c1 complex that can be activated by mito-
chondrial dysfunction, whereas TBC1D1 and ACACB
are primarily phosphorylated by the a2b2c3 complex,
which is activated instead by muscle contraction.
Therefore, different AMPK complexes at distinct loca-
tions in skeletal muscle not only respond to different
inputs, but also have different outputs.
Finally, from analysis using cBioPortal, it is less
obvious (compared to the analysis of a and b subunits
described above) that there is any selection for specific
alterations of any of the three genes encoding c sub-
units in different cancers.
Conclusions and perspectives
Although much remains to be learned, the results dis-
cussed in this review suggest that the numerous het-
erotrimeric combinations of AMPK subunit isoforms
(up to 12, or more when counting variants derived
from single genes) may have different subcellular
locations, different inputs and outputs, and different
functions. A particularly intriguing feature is that
genes encoding certain AMPK-a and -b isoforms (i.e.
a1 and b2) are frequently amplified together in differ-
ent cancers, whereas others (i.e. a2 and b1) are more
commonly mutated instead. These findings make little
sense unless these isoforms have different inputs and/
or outputs. Interestingly, except for LKB1 and PTEN
all other proteins mentioned in this review, including
CAMKK2, GYS1, ULK1, TBC1D1 and ACACB,
are also 2R-ohnologues [79]. This raises the question
as to whether AMPK variants display selectivity for
different sisters in each 2R-family of regulators, inter-
actors or substrates. Deciphering how different
AMPK isoforms are positioned within their sub-net-
work contexts may be key to understanding their dif-
ferential roles in cancers [80].
Acknowledgements
DGH is supported by a Senior Investigator Award
(097726) from the Wellcome Trust and a Programme
Grant (C37030/A15101) from Cancer Research UK.
CM thanks the University of Dundee Wellcome Trust
Institutional Strategic Support Fund and the UK
Medical Research Council Developmental Pathway
Funding Scheme (G0801767) for support.
Author contributions
FAR performed some of the recent experiments cov-
ered in the review, and made suggestions for revision
of the draft version. CM wrote the first draft of the
section on 2R ohnologues, drew Fig. 1, and made
many suggestions for improvement. DGH conceived
the original idea, wrote most of the first draft and cre-
ated Figs 2–5.
References
1 Hardie DG (2015) Molecular pathways: is AMPK a
friend or a foe in cancer? Clin Cancer Res 21, 3836–
3840.
2 Hardie DG (2014) AMPK–sensing energy while talking
to other signaling pathways. Cell Metab 20, 939–952.
3 Hardie DG, Schaffer BE & Brunet A (2016) AMPK: an
energy-sensing pathway with multiple inputs and
outputs. Trends Cell Biol 26, 190–201.
4 Pan DA & Hardie DG (2002) A homologue of AMP-
activated protein kinase in Drosophila melanogaster is
sensitive to AMP and is activated by ATP depletion.
Biochem J 367, 179–186.
5 Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell
BJ, Teh T, House CM, Fernandez CS, Cox T, Witters
LA et al. (1996) Mammalian AMP-activated protein
kinase subfamily. J Biol Chem 271, 611–614.
6 Thornton C, Snowden MA & Carling D (1998)
Identification of a novel AMP-activated protein kinase
beta subunit isoform that is highly expressed in skeletal
muscle. J Biol Chem 273, 12443–12450.
7 Cheung PCF, Salt IP, Davies SP, Hardie DG & Carling
D (2000) Characterization of AMP-activated protein
kinase g subunit isoforms and their role in AMP
binding. Biochem J 346, 659–669.
8 Rajamohan F, Reyes AR, Frisbie RK, Hoth LR,
Sahasrabudhe P, Magyar R, Landro JA, Withka JM,
Caspers NL, Calabrese MF et al. (2015) Probing the
enzyme kinetics, allosteric modulation and activation of
alpha-1 and alpha-2 subunit containing AMP-activated
protein kinase (AMPK) heterotrimeric complexes by
pharmacological and physiological activators. Biochem
J 473, 581–592.
9 Birk JB & Wojtaszewski JF (2006) Predominant
alpha-1/beta-2/gamma-3 AMPK activation during
exercise in human skeletal muscle. J Physiol 577,
1021–1032.
2997The FEBS Journal 283 (2016) 2987–3001 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
F. A. Ross et al. AMPK: a cellular energy sensor in 12 flavours
10 Dehal P & Boore JL (2005) Two rounds of whole
genome duplication in the ancestral vertebrate. PLoS
Biol 3, e314.
11 Ohno S (1970) Evolution by Gene Duplication.
Springer-Verlag, Berlin.
12 Putnam NH, Butts T, Ferrier DE, Furlong RF,
Hellsten U, Kawashima T, Robinson-Rechavi M,
Shoguchi E, Terry A, Yu JK et al. (2008) The
amphioxus genome and the evolution of the chordate
karyotype. Nature 453, 1064–1071.
13 Huminiecki L & Heldin CH (2010) 2R and remodeling
of vertebrate signal transduction engine. BMC Biol 8,
146.
14 Tinti M, Johnson C, Toth R, Ferrier DE &
Mackintosh C (2012) Evolution of signal multiplexing
by 14-3-3-binding 2R-ohnologue protein families in the
vertebrates. Open Biol 2, 120103.
15 Madeira F, Tinti M, Murugesan G, Berrett E, Stafford
M, Toth R, Cole C, MacKintosh C & Barton GJ
(2015) 14-3-3-Pred: improved methods to predict 14-3-
3-binding phosphopeptides. Bioinformatics 31, 2276–
2283.
16 Makino T & McLysaght A (2010) Ohnologs in the
human genome are dosage balanced and frequently
associated with disease. Proc Natl Acad Sci USA 107,
9270–9274.
17 Gowans GJ, Hawley SA, Ross FA & Hardie DG
(2013) AMP is a true physiological regulator of AMP-
activated protein kinase by both allosteric activation
and enhancing net phosphorylation. Cell Metab 18,
556–566.
18 Ross FA, Jensen TE & Hardie DG (2016) Differential
regulation by AMP and ADP of AMPK complexes
containing different gamma subunit isoforms. Biochem
J 473, 189–199.
19 Xiao B, Sanders MJ, Underwood E, Heath R, Mayer
FV, Carmena D, Jing C, Walker PA, Eccleston JF,
Haire LF et al. (2011) Structure of mammalian AMPK
and its regulation by ADP. Nature 472, 230–233.
20 Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, Tam
S & Kemp BE (2011) AMPK is a direct adenylate
charge-regulated protein kinase. Science 332, 1433–
1435.
21 Li X, Wang L, Zhou XE, Ke J, de Waal PW, Gu X,
Tan MH, Wang D, Wu D, Xu HE et al. (2015)
Structural basis of AMPK regulation by adenine
nucleotides and glycogen. Cell Res 25, 50–66.
22 Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF,
Underwood E, Patel BR, Heath RB, Walker PA,
Hallen S et al. (2013) Structural basis of AMPK
regulation by small molecule activators. Nat Commun 4,
3017.
23 Calabrese MF, Rajamohan F, Harris MS, Caspers NL,
Magyar R, Withka JM, Wang H, Borzilleri KA,
Sahasrabudhe PV, Hoth LR et al. (2014) Structural
basis for AMPK activation: natural and synthetic
ligands regulate kinase activity from opposite poles by
different molecular mechanisms. Structure 22, 1161–
1172.
24 Chen L, Jiao ZH, Zheng LS, Zhang YY, Xie ST, Wang
ZX & Wu JW (2009) Structural insight into the
autoinhibition mechanism of AMP-activated protein
kinase. Nature 459, 1146–1149.
25 Oakhill JS, Chen ZP, Scott JW, Steel R, Castelli LA,
Ling N, Macaulay SL & Kemp BE (2010) beta-Subunit
myristoylation is the gatekeeper for initiating metabolic
stress sensing by AMP-activated protein kinase
(AMPK). Proc Natl Acad Sci USA 107, 19237–19241.
26 Zhang CS, Jiang B, Li M, Zhu M, Peng Y, Zhang YL,
Wu YQ, Li TY, Liang Y, Lu Z et al. (2014) The
lysosomal v-ATPase-Ragulator complex Is a common
activator for AMPK and mTORC1, acting as a switch
between catabolism and anabolism. Cell Metab 20,
526–540.
27 Liang J, Xu ZX, Ding Z, Lu Y, Yu Q, Werle KD,
Zhou G, Park YY, Peng G, Gambello MJ et al. (2015)
Myristoylation confers noncanonical AMPK functions
in autophagy selectivity and mitochondrial surveillance.
Nat Commun 6, 7926.
28 Koay A, Rimmer KA, Mertens HD, Gooley PR &
Stapleton D (2007) Oligosaccharide recognition and
binding to the carbohydrate binding module of AMP-
activated protein kinase. FEBS Lett 581, 5055–5059.
29 Hudson ER, Pan DA, James J, Lucocq JM, Hawley
SA, Green KA, Baba O, Terashima T & Hardie DG
(2003) A novel domain in AMP-activated protein
kinase causes glycogen storage bodies similar to those
seen in hereditary cardiac arrhythmias. Curr Biol 13,
861–866.
30 Polekhina G, Gupta A, Michell BJ, van Denderen B,
Murthy S, Feil SC, Jennings IG, Campbell DJ, Witters
LA, Parker MW et al. (2003) AMPK b-subunit targets
metabolic stress-sensing to glycogen. Curr Biol 13, 867–
871.
31 Jorgensen SB, Nielsen JN, Birk JB, Olsen GS, Viollet
B, Andreelli F, Schjerling P, Vaulont S, Hardie DG,
Hansen BF et al. (2004) The a2-50AMP-activated
protein kinase is a site 2 glycogen synthase kinase in
skeletal muscle and is responsive to glucose loading.
Diabetes 53, 3074–3081.
32 Bultot L, Guigas B, Von Wilamowitz-Moellendorff A,
Maisin L, Vertommen D, Hussain N, Beullens M,
Guinovart JJ, Foretz M, Viollet B et al. (2012) AMP-
activated protein kinase phosphorylates and
inactivates liver glycogen synthase. Biochem J 443,
193–203.
33 Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham
M, Dickinson R, Adler A, Gagne G, Iyengar R et al.
(2006) Identification and characterization of a small
molecule AMPK activator that treats key components
2998 The FEBS Journal 283 (2016) 2987–3001 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
AMPK: a cellular energy sensor in 12 flavours F. A. Ross et al.
of type 2 diabetes and the metabolic syndrome. Cell
Metab 3, 403–416.
34 Hawley SA, Fullerton MD, Ross FA, Schertzer JD,
Chevtzoff C, Walker KJ, Peggie MW, Zibrova D,
Green KA, Mustard KJ et al. (2012) The ancient drug
salicylate directly activates AMP-activated protein
kinase. Science 336, 918–922.
35 Scott JW, Hawley SA, Green KA, Anis M, Stewart G,
Scullion GA, Norman DG & Hardie DG (2004) CBS
domains form energy-sensing modules whose binding of
adenosine ligands is disrupted by disease mutations. J
Clin Invest 113, 274–284.
36 Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C,
Walker PA, Haire L, Eccleston JF, Davis CT et al.
(2007) Structural basis for AMP binding to mammalian
AMP-activated protein kinase. Nature 449, 496–500.
37 Chen L, Wang J, Zhang YY, Yan SF, Neumann D,
Schlattner U, Wang ZX & Wu JW (2012) AMP-
activated protein kinase undergoes nucleotide-
dependent conformational changes. Nat Struct Mol Biol
19, 716–718.
38 Chen L, Xin FJ, Wang J, Hu J, Zhang YY, Wan S,
Cao LS, Lu C, Li P, Yan SF et al. (2013) Conserved
regulatory elements in AMPK. Nature 498, E8–E10.
39 Xin FJ, Wang J, Zhao RQ, Wang ZX & Wu JW (2013)
Coordinated regulation of AMPK activity by multiple
elements in the alpha-subunit. Cell Res 23, 1237–1240.
40 Riek U, Scholz R, Konarev P, Rufer A, Suter M,
Nazabal A, Ringler P, Chami M, Muller SA, Neumann
D et al. (2008) Structural properties of AMP-activated
protein kinase. Dimerization, molecular shape, and
changes upon ligand binding. J Biol Chem 283, 18331–
18343.
41 Imamura K, Ogura T, Kishimoto A, Kaminishi M &
Esumi H (2001) Cell cycle regulation via p53
phosphorylation by a 50-AMP activated protein kinase
activator, 5-aminoimidazole- 4-carboxamide-1-beta-d-
ribofuranoside, in a human hepatocellular carcinoma
cell line. Biochem Biophys Res Commun 287, 562–567.
42 Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y,
Birnbaum MJ & Thompson CB (2005) AMP-activated
protein kinase induces a p53-dependent metabolic
checkpoint. Mol Cell 18, 283–293.
43 Faubert B, Boily G, Izreig S, Griss T, Samborska B,
Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B
et al. (2012) AMPK is a negative regulator of the
Warburg effect and suppresses tumor growth in vivo.
Cell Metab 17, 113–124.
44 Hawley SA, Ross FA, Gowans GJ, Tibarewal P,
Leslie NR & Hardie DG (2014) Phosphorylation by
Akt within the ST loop of AMPK-a1 down-regulates
its activation in tumour cells. Biochem J 459, 275–
287.
45 Pineda CT, Ramanathan S, Fon Tacer K, Weon JL,
Potts MB, Ou YH, White MA & Potts PR (2015)
Degradation of AMPK by a cancer-specific ubiquitin
ligase. Cell 160, 715–728.
46 Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le
T, Orduna J, Foretz M & Viollet B (2006) 50-AMP-
activated protein kinase (AMPK) is induced by low-
oxygen and glucose deprivation conditions found in
solid-tumor microenvironments. Mol Cell Biol 26,
5336–5347.
47 Jeon SM & Hay N (2015) The double-edged sword of
AMPK signaling in cancer and its therapeutic
implications. Arch Pharm Res 38, 346–357.
48 Monteverde T, Muthalagu N, Port J & Murphy DJ
(2015) Evidence of cancer promoting roles for AMPK
and related kinases. FEBS J 282, 4658–4671.
49 Saito Y, Chapple RH, Lin A, Kitano A & Nakada D
(2015) AMPK protects leukemia-initiating cells in
myeloid leukemias from metabolic stress in the bone
marrow. Cell Stem Cell 17, 585–596.
50 Fisher KW, Das B, Kim HS, Clymer BK, Gehring
D, Smith DR, Costanzo-Garvey DL, Fernandez MR,
Brattain MG, Kelly DL et al. (2015) AMPK
promotes aberrant PGC1beta expression to support
human colon tumor cell survival. Mol Cell Biol 35,
3866–3879.
51 Woods A, Salt I, Scott J, Hardie DG & Carling D
(1996) The alpha1 and alpha2 isoforms of the AMP-
activated protein kinase have similar activities in rat
liver but exhibit differences in substrate specificity
in vitro. FEBS Lett 397, 347–351.
52 Foretz M, Guihard S, Leclerc J, Fauveau V, Couty JP,
Andris F, Gaudry M, Andreelli F, Vaulont S & Viollet
B (2010) Maintenance of red blood cell integrity by
AMP-activated protein kinase alpha1 catalytic subunit.
FEBS Lett 584, 3667–3671.
53 Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen
A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M
et al. (2003) The AMP-activated protein kinase a2
catalytic subunit controls whole-body insulin sensitivity.
J Clin Invest 111, 91–98.
54 Lopez M, Varela L, Vazquez MJ, Rodriguez-Cuenca S,
Gonzalez CR, Velagapudi VR, Morgan DA,
Schoenmakers E, Agassandian K, Lage R et al. (2010)
Hypothalamic AMPK and fatty acid metabolism
mediate thyroid regulation of energy balance. Nat Med
16, 1001–1008.
55 Martinez de Morentin PB, Gonzalez-Garcia I, Martins
L, Lage R, Fernandez-Mallo D, Martinez-Sanchez N,
Ruiz-Pino F, Liu J, Morgan DA, Pinilla L et al. (2014)
Estradiol regulates brown adipose tissue thermogenesis
via hypothalamic AMPK. Cell Metab 20, 41–53.
56 Beiroa D, Imbernon M, Gallego R, Senra A, Herranz
D, Villaroya F, Serrano M, Ferno J, Salvador J,
Escalada J et al. (2014) GLP-1 agonism stimulates
brown adipose tissue thermogenesis and browning
through hypothalamic AMPK. Diabetes 63, 3346–3358.
2999The FEBS Journal 283 (2016) 2987–3001 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
F. A. Ross et al. AMPK: a cellular energy sensor in 12 flavours
57 Viollet B, Athea Y, Mounier R, Guigas B,
Zarrinpashneh E, Horman S, Lantier L, Hebrard S,
Devin-Leclerc J, Beauloye C et al. (2009) AMPK:
lessons from transgenic and knockout animals. Front
Biosci 14, 19–44.
58 Salt IP, Celler JW, Hawley SA, Prescott A, Woods A,
Carling D & Hardie DG (1998) AMP-activated protein
kinase – greater AMP dependence, and preferential
nuclear localization, of complexes containing the a2
isoform. Biochem J 334, 177–187.
59 Turnley AM, Stapleton D, Mann RJ, Witters LA,
Kemp BE & Bartlett PF (1999) Cellular distribution
and developmental expression of AMP-activated
protein kinase isoforms in mouse central nervous
system. J Neurochem 72, 1707–1716.
60 Ai H, Ihlemann J, Hellsten Y, Lauritzen HP, Hardie
DG, Galbo H & Ploug T (2002) Effect of fiber type
and nutritional state on AICAR- and contraction-
stimulated glucose transport in rat muscle. Am J
Physiol 282, E1291–E1300.
61 Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T &
Minokoshi Y (2007) Leptin stimulates fatty acid
oxidation and peroxisome proliferator-activated
receptor alpha gene expression in mouse C2C12
myoblasts by changing the subcellular localization of
the alpha2 form of AMP-activated protein kinase. Mol
Cell Biol 27, 4317–4327.
62 Lamia KA, Sachdeva UM, DiTacchio L, Williams EC,
Alvarez JG, Egan DF, Vasquez DS, Juguilon H, Panda
S, Shaw RJ et al. (2009) AMPK regulates the circadian
clock by cryptochrome phosphorylation and
degradation. Science 326, 437–440.
63 Kazgan N, Williams T, Forsberg LJ & Brenman JE
(2010) Identification of a nuclear export signal in the
catalytic subunit of AMP-activated protein kinase. Mol
Biol Cell 21, 3433–3442.
64 Mahboubi H, Barise R & Stochaj U (2015) 50-AMP-
activated protein kinase alpha regulates stress
granule biogenesis. Biochim Biophys Acta 1853, 1725–
17237.
65 Horman S, Vertommen D, Heath R, Neumann D,
Mouton V, Woods A, Schlattner U, Wallimann T,
Carling D, Hue L et al. (2006) Insulin antagonizes
ischemia-induced Thr172 phosphorylation of AMP-
activated protein kinase alpha-subunits in heart via
hierarchical phosphorylation of Ser485/491. J Biol
Chem 281, 5335–5340.
66 Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO,
Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson
E et al. (2012) The cBio cancer genomics portal: an
open platform for exploring multidimensional cancer
genomics data. Cancer Discov 2, 401–404.
67 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B,
Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E
et al. (2013) Integrative analysis of complex cancer
genomics and clinical profiles using the cBioPortal. Sci
Signal 6, pl1.
68 Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ,
Lehar J, Kryukov GV, Sonkin D et al. (2012) The
Cancer Cell Line Encyclopedia enables predictive
modelling of anticancer drug sensitivity. Nature 483,
603–607.
69 Phoenix KN, Devarakonda CV, Fox MM, Stevens LE
& Claffey KP (2012) AMPKalpha2 suppresses murine
embryonic fibroblast transformation and tumorigenesis.
Genes Cancer 3, 51–62.
70 Mobbs JI, Koay A, Di Paolo A, Bieri M, Petrie EJ,
Gorman MA, Doughty L, Parker MW, Stapleton D,
Griffin MD et al. (2015) Determinants of
oligosaccharide specificity of the carbohydrate binding
modules of AMP-activated protein kinase. Biochem J
468, 245–257.
71 Scott JW, van Denderen BJ, Jorgensen SB, Honeyman
JE, Steinberg GR, Oakhill JS, Iseli TJ, Koay A,
Gooley PR, Stapleton D et al. (2008) Thienopyridone
drugs are selective activators of AMP-activated protein
kinase beta1-containing complexes. Chem Biol 15,
1220–1230.
72 Yu H, Fujii N, Hirshman MF, Pomerleau JM &
Goodyear LJ (2004) Cloning and characterization of
mouse 50-AMP-activated protein kinase gamma3
subunit. Am J Physiol Cell Physiol 286, C283–
C292.
73 Pinter K, Grignani RT, Czibik G, Farza H, Watkins H
& Redwood C (2012) Embryonic expression of AMPK
gamma subunits and the identification of a novel
gamma2 transcript variant in adult heart. J Mol Cell
Cardiol 53, 342–349.
74 Pinter K, Grignani RT, Watkins H & Redwood C
(2013) Localisation of AMPK gamma subunits in
cardiac and skeletal muscles. J Muscle Res Cell Motil
34, 369–378.
75 Gregor M, Zeold A, Oehler S, Marobela KA, Fuchs P,
Weigel G, Hardie DG & Wiche G (2006) Plectin
scaffolds recruit energy-controlling AMP-activated
protein kinase (AMPK) in differentiated myofibres.
J Cell Sci 119, 1864–1875.
76 Pinter K, Jefferson A, Czibik G, Watkins H &
Redwood C (2012) Subunit composition of AMPK
trimers present in the cytokinetic apparatus:
implications for drug target identification. Cell Cycle
11, 917–921.
77 Pang T, Zhang ZS, Gu M, Qiu BY, Yu LF, Cao PR,
Shao W, Su MB, Li JY, Nan FJ et al. (2008) Small
molecule antagonizes autoinhibition and activates
AMP-activated protein kinase in cells. J Biol Chem 283,
16051–16060.
78 Jensen TE, Ross FA, Kleinert M, Sylow L, Knudsen
JR, Gowans GJ, Hardie DG & Richter EA (2015) PT-1
3000 The FEBS Journal 283 (2016) 2987–3001 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
AMPK: a cellular energy sensor in 12 flavours F. A. Ross et al.
selectively activates AMPK-gamma1 complexes in
mouse skeletal muscle, but activates all three gamma
subunit complexes in cultured human cells by inhibiting
the respiratory chain. Biochem J 467, 461–472.
79 Singh PP, Arora J & Isambert H (2015) Identification
of ohnolog genes originating from whole genome
duplication in early vertebrates, based on synteny
comparison across multiple genomes. PLoS Comput
Biol 11, e1004394.
80 Tinti M, Dissanayake K, Synowsky S, Albergante L &
MacKintosh C (2014) Identification of 2R-ohnologue
gene families displaying the same mutation-load skew
in multiple cancers. Open Biol 4, 140029.
81 Guindon S, Dufayard JF, Lefort V, Anisimova M,
Hordijk W & Gascuel O (2010) New algorithms and
methods to estimate maximum-likelihood phylogenies:
assessing the performance of PhyML 3.0. Syst Biol 59,
307–321.
3001The FEBS Journal 283 (2016) 2987–3001 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
F. A. Ross et al. AMPK: a cellular energy sensor in 12 flavours
